The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.
Edward S. Kim
Consultant or Advisory Role - Boehringer Ingelheim; Genentech; Lilly; OSI Pharmaceuticals
Research Funding - Genentech; Lilly; OSI Pharmaceuticals
Marcus A. Neubauer
Employment or Leadership Position - USON Med Director
Allen Lee Cohn
No relevant relationships to disclose
Lee Steven Schwartzberg
No relevant relationships to disclose
Lawrence E. Garbo
No relevant relationships to disclose
John Robert Caton
No relevant relationships to disclose
Francisco Robert
Research Funding - University of Alabama at Birmingham
Terry Katz
Employment or Leadership Position - ImClone Systems
Sreenivas Chittoor
No relevant relationships to disclose
Lorinda Simms
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Scott Saxman
Employment or Leadership Position - Lilly
Stock Ownership - Lilly